

THALASSEMIA: STILL A CHALLENGE

Fazal-ur-Rahman Khan

Department of Paediatrics, Gomal Medical College, D. I. Khan, Pakistan

Beta thalassemia is the most common single gene disorder in Pakistan with a gene frequency of 5-8% and about 8-10 million carriers in the country.¹ It has become a worldwide clinical problem due to increasing immigration of ethnic groups with high prevalence of thalassemia.^{2,3} Over the past three decades, regular blood transfusions and iron chelation has dramatically improved the quality of life and transformed thalassaemia from a rapidly fatal disease in early childhood to a chronic disease compatible with prolonged life.^{1,4} Today life expectancy varies between 25-55 years, depending on the compliance with medical treatment.⁴ Despite increased life expectancy, complications keep arising. These relate to inadequate transfusions, transfusion-related infections, allo-sensitization, iron-overload related cardiac, endocrine and liver disturbances and toxicities of iron chelators.^{4,5} Many of these problems are strongly age dependent.⁵

Heart disease is the most important complication and the main determinant of survival. It is responsible for more than half of the deaths.^{6,7} It may take the form of cardiomyopathy, pulmonary hypertension, heart failure, arrhythmias, pericarditis and myocarditis.^{6,7,8,9} Although iron overload is the main cause but other factors; genetic, immune or infective, may also be important.¹⁰

Endocrine complications include diabetes mellitus, hypothyroidism, hypoparathyroidism, hypogonadism and delayed puberty.^{11,12} These complications have contributed little to morbidity and mortality in the past; however as a result of increased longevity, these have become more common and contribute significantly to the morbidity in these patients.¹³ Endocrine complications along with osteoporosis, trace elements deficiency and other metabolic disturbances also lead to growth failure and short stature.^{11,14}

Less significant complications include hepatic involvement,^{15,16} neurological complications,¹⁷ and psychological manifestations.¹⁸

In short, beta thalassemia has a spectrum of varied manifestations and complications. The importance of thalassemia in Pakistan is masked by infections and nutritional deficiencies.^{19,20} We need to develop preventive strategies like pre-marital

screening, genetic counseling and ante-natal diagnosis. A part from early diagnosis, there is a need to increase the therapeutic facilities like blood transfusions, chelation therapy and bone marrow transplant.

It is really a great challenge and needs an organized plan for action.

REFERENCES

1. Satwani H, Raza J, Alam M, Kidwai A. Endocrinal complications in thalassemias: Frequency and association with ferritin levels. *Pak Ped J* 2005; 29: 113-19.
2. Hahalis G, Alexopoulos D, Kremastinos DT, Zoumbos NC. Heart failure in beta thalassemia syndromes: a decade of progress. *Am J Med* 2005; 118: 957-67.
3. Pearson HA, Cohen AR, Giardina PJ, Kazazian HH. The changing profile of homozygous beta thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. *Pediatrics* 1996; 97: 352-6.
4. Agarwal MB. Advances in management of thalassemia (Editorial). *Indian Pediatrics* 2004; 41: 989-92.
5. Cunningham MJ, Macklin EA, Neufeld EJ, Cohen AR. Complications of beta thalassemia major in North America. *Blood* 2004; 104: 34-39.
6. Aessopos A, Farmrkis D, Deftereos S, Tsironi M, Tassiopoulos S, Moyssakis I, et al. Thalassemia heart disease, a comparative evaluation of thalassemia major and thalassemia intermedia. *Chest* 2005; 127: 1523-30.
7. Borgne-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, et al. Survival and complications in thalassemia. *Ann N Y Acad Sci* 2005; 1054: 40-47.
8. Olivieri NF, Nathan DG, MacMillan JC, Wayne AS, Liu PP, McGee A, et al. Survival in medically treated patients with homozygous beta thalassemia. *New Eng J Med* 1994; 331: 574-78.
9. Chern JP, Su S, Lin KH, Chang SH, Lu MY, Jou ST, et al. Survival, mortality and complications in patients with beta thalassemia major in northern Taiwan. *Pediatr Blood Cancer* 2006; 45: 53-56.

-
10. Kremastinos DT, Flevari P, Spyropoulou M, Vrettou H, Tsiapras D, Stavropoulos-Giokos CG. Association of heart failure in homozygous beta thalassemia with the major histocompatibility complex. *Circulation* 1999; 100: 2074-78.
 11. Shamshirsaz AA, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, et al. Metabolic and endocrinologic complications in beta thalassemia major: a multicenter study in Tehran. *BMC Endocrine Disorders* 2003; 3: 23-34.
 12. De Sanctis V, Vullo C, Katz M, Wonke B, Tanas R, Bangi B. Gonadal function in patients with beta thalassemia major. *J Clin Pathol* 1988; 41: 133-37.
 13. Mohammadian S, Bazrafshan HR, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. *Pediatr Endocrinol Metab* 2003; 16: 957-64.
 14. Low Louis CK. Growth of children with beta thalassemia major. *Indian J Pediatr* 2005; 72: 159-64.
 15. Perifanis V, Tziomalos K, Tsatra I, Karyda S, Patsiaoura K, Athanassiou-Metaxa M. Prevalence and severity of liver disease in patients with beta thalassemia major. A single-institution fifteen year experience (letter). *Haematologica* 2005; 90: 1136-38.
 16. Prati D, Maggioni M, Milani S, Cerino M, Cianciulli P, Coggi G et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta thalassemia. A multicenter study of 117 cases. *Haematologica* 2004; 89: 1179-86.
 17. Zafeiriou DI, Economou M, Athanassiou-Metaxa M. Neurological complications in beta thalassemia. *Brain Dev* 2006; 28: 477-81.
 18. Moorjani JD, Chithira I. Neurotic manifestations in adolescents with thalassemia major. *Indian J Pediatr* 2006; 73: 603-7.
 19. Rahman M, Lodhi Y. Prospects and future of conservative management of beta thalassemia major in a developing country. *Pak J Med Sci* 2004; 20: 105-12.
 20. Imran M. Hereditary anemias in North West Frontier Province of Pakistan. *J Postgrad Med Inst Peshawar* 1986; 1: 104-6.